The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The perinatology CME at Navi Mumbai brought together more than 100 obstetricians, pediatricians, and neonatologists
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
Funding to accelerate growth of concierge-style private health services and Aayu’s paperless hospital infrastructure platform
The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
New Yamuna Vihar facility to train 40 students annually through diploma-led, hands-on renal care education
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
CDSCO-cleared BSM-5700 series targets ICU, NICU, ER, OR and digital health integration under ABDM
Collaboration aims to align hospital staff learning with NABH 6th Edition standards, patient safety, and measurable quality outcomes
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Subscribe To Our Newsletter & Stay Updated
